Gynecologic Cancers

Quick Answer

FDG-PET/CT is most valuable in locally advanced cervical cancer (nodal and distant staging, radiotherapy planning, and post-treatment response/recurrence) — where para-aortic nodal uptake directly changes the radiotherapy field — and in ovarian cancer recurrence, especially with a rising CA-125 and negative or equivocal conventional imaging. In endometrial cancer, its role is chiefly detecting nodal/distant disease in high-risk or recurrent settings.

Definition

The three principal gynecologic cancers imaged in nuclear medicine are cervical (squamous cell or adenocarcinoma of the uterine cervix), ovarian / fallopian-tube / primary-peritoneal carcinoma (dominated by high-grade serous carcinoma), and endometrial (uterine corpus) carcinoma. They differ markedly in etiology, spread pattern, and imaging role.

Synonyms

Cervical carcinoma; ovarian/tubal/peritoneal high-grade serous carcinoma (HGSC); endometrial (uterine) carcinoma — type 1 (endometrioid) and type 2 (serous/clear-cell).

Epidemiology

• Cervical: strongly HPV-driven and largely screening-/vaccine-preventable; a major global cancer burden, disproportionately affecting under-screened populations and younger women.
• Ovarian: relatively less common but the most lethal gynecologic cancer, because it usually presents at an advanced stage; HGSC predominates.
• Endometrial: the most common gynecologic cancer in high-income countries, rising with obesity, typically presenting early with postmenopausal bleeding.

Etiology & Risk Factors

• Cervical: persistent high-risk HPV (16/18), smoking, immunosuppression.
• Ovarian: BRCA1/2 and family history, Lynch syndrome, and reproductive/ovulation factors; risk-reducing salpingo-oophorectomy in carriers.
• Endometrial: unopposed estrogen (obesity, PCOS, tamoxifen, nulliparity), and Lynch syndrome (MMR deficiency).

Pathophysiology

• Cervical cancer arises at the transformation zone via HPV E6/E7 oncoprotein–driven inactivation of p53/Rb; spreads locally and via lymphatics (pelvic → para-aortic nodes), which is why nodal mapping alters radiotherapy.
• Ovarian HGSC frequently originates in the fallopian-tube fimbria (serous tubal intraepithelial carcinoma), is TP53-mutated and often BRCA/HRD-associated, and disseminates transcoelomically (peritoneal carcinomatosis).
• Endometrial type 1 (endometrioid) is estrogen-driven and indolent; type 2 (serous/clear-cell) is aggressive and estrogen-independent.

Genetics & Molecular Biology

• Cervical: HPV integration; PD-L1 expression (immunotherapy).
• Ovarian: BRCA1/2 and homologous-recombination deficiency (HRD) predict PARP-inhibitor benefit; TP53 near-universal in HGSC.
• Endometrial (TCGA molecular classes): POLE-ultramutated (excellent prognosis), MMR-deficient/MSI-high (Lynch; immunotherapy-responsive), p53-abnormal (serous-like, poor), and no-specific-molecular-profile.

Histopathology

Cervical: squamous cell carcinoma (majority) and adenocarcinoma. Ovarian: high-grade serous (most common), endometrioid, clear-cell, mucinous, low-grade serous. Endometrial: endometrioid (graded 1–3) and serous/clear-cell (type 2). Molecular classification increasingly refines endometrial prognosis and therapy.

Clinical Presentation

• Cervical: abnormal/post-coital bleeding, discharge; advanced disease with pelvic pain or hydronephrosis.
• Ovarian: insidious bloating, early satiety, pelvic/abdominal distension — usually late-stage (peritoneal disease, ascites).
• Endometrial: postmenopausal bleeding (early, favorable presentation).

Laboratory Findings

• CA-125 (ovarian — baseline, response, and recurrence trigger; also HE4/ROMA); SCC-Ag (cervical squamous).
• HPV/cytology screening (cervical); MMR/molecular testing (endometrial, per TCGA classes).

Imaging Findings by Modality

• MRI: local staging of cervical (tumor size, parametrial/stromal invasion) and endometrial (myometrial invasion) disease; pelvic-mass characterization.
• Ultrasound: first-line for adnexal masses and endometrial thickness.
• CT: abdominal/peritoneal and distant staging (ovarian burden).
• FDG-PET/CT: cervical nodal/distant staging and RT planning, ovarian recurrence (rising CA-125), and high-risk/recurrent endometrial disease.

Radiopharmaceutical Uptake Mechanisms

FDG reflects tumor glucose metabolism. Interpretation must account for cyclical physiologic endometrial and ovarian uptake (menstrual phase, ovulation, corpus-luteum cyst), bowel activity, and ureteral/bladder excretion that can obscure pelvic nodes. FAPI (stromal fibroblast activation protein) shows promise for small-volume peritoneal disease that FDG under-detects.

Typical PET Tracers

Typical SPECT Tracers

• Sentinel-node lymphoscintigraphy (Tc-99m-sulfur colloid / tilmanocept ± SPECT/CT) — increasingly used for cervical, endometrial, and vulvar nodal staging.

Therapy Indications

• Cervical: early disease — surgery (radical hysterectomy) or radiotherapy; locally advanced — concurrent chemoradiation + brachytherapy; advanced/recurrent — chemotherapy ± bevacizumab and immunotherapy (PD-L1).
• Ovarian: cytoreductive surgery + platinum/taxane chemotherapy; PARP-inhibitor maintenance (BRCA/HRD) and bevacizumab.
• Endometrial: surgery (± nodal assessment) and risk-adapted adjuvant therapy; immunotherapy for MMR-deficient/advanced disease.

Theranostics

No established radioligand therapy in gynecologic cancer; the nuclear-medicine contribution is diagnostic and management-defining (nodal staging that reshapes radiotherapy, recurrence localization). FAPI-directed imaging (and potential therapy) for peritoneal disease is an emerging avenue.

Differential Diagnosis (of pelvic FDG uptake)

• Physiologic cyclical endometrial/ovarian uptake (correlate with menstrual history), functional ovarian cysts, and corpus luteum.
• Bowel physiologic/inflammatory uptake and diverticulitis.
• Ureteral/bladder excreted activity mimicking or masking pelvic nodes.
• Post-surgical/radiation change and benign fibroids (usually low-avid).

Reporting Checklist

• For cervical: report pelvic vs para-aortic nodal status explicitly — it changes the radiotherapy field/extent — plus distant disease and FIGO context.
• For ovarian: localize recurrence and correlate with CA-125; comment on peritoneal disease and FDG's partial-volume limits.
• For endometrial: focus on nodal/distant disease in high-risk/recurrent settings.
• Address cyclical physiologic uptake, bowel, and urinary-activity confounders; consider hydration/diuretic/delayed technique for pelvic nodes.

Prognosis

Stage (FIGO) dominates outcome across all three. Cervical cancer is curable when localized and screen-detected. Ovarian cancer's poor prognosis reflects late presentation; BRCA/HRD status and optimal cytoreduction improve outcomes. Endometrial cancer is often curable early (postmenopausal bleeding presentation), with the TCGA molecular class (POLE favorable → p53-abnormal unfavorable) refining prognosis and therapy.

Board facts at a glance

Role by primary site, plus the shared pelvic pitfalls:

Board Pearls

The two strongest gynecologic indications are locally advanced cervical cancer (nodal/distant staging, RT planning, surveillance) — where para-aortic nodal uptake directly changes the radiotherapy field — and ovarian recurrence with a rising CA-125 and negative/equivocal conventional imaging. Endometrial use is chiefly high-risk or recurrent nodal/distant disease.

Physiologic pelvic uptake is cyclical — endometrial/ovarian FDG varies with the menstrual phase and ovulation — so correlate with menstrual history before calling disease.

Small-volume peritoneal disease is under-detected by FDG (partial-volume), an area where FAPI shows promise, and ureteral/bladder excreted activity can obscure pelvic nodes (hydration, diuretic, or delayed technique helps). Sentinel-node mapping is increasingly used for cervical/endometrial/vulvar nodal staging.

Related Pages

• Tracer: FDG and (emerging) FAPI.
• Related studies: Lymphoscintigraphy & sentinel node (cervical/endometrial/vulvar).
• Pitfalls: Pearls, pitfalls & normal variants, Incidental findings on FDG-PET.

Figure / Diagram Suggestions

• A cervical nodal map (pelvic → para-aortic) showing how para-aortic disease extends the RT field.
• The endometrial TCGA molecular classes and their prognosis.
• A pelvic physiologic-uptake plate (cyclical endometrium/ovary, bowel, ureter/bladder).

Common Pitfalls

• Ovarian FDG uptake in a postmenopausal woman is abnormal — the quiescent postmenopausal ovary should not be avid, so do not dismiss it as physiologic (unlike cyclical premenopausal uptake).
• FDG-low histologies — mucinous and low-grade serous ovarian carcinomas, and clear-cell tumors — can be falsely negative; a normal SUV does not exclude disease.
• Benign FDG-avid mimics — endometriosis, tubo-ovarian abscess, dermoid, and cellular/degenerating fibroids — can produce false-positive pelvic uptake.
• Post-radiation/brachytherapy inflammation in the cervix and reactive pelvic nodes causes false positives — respect an adequate interval after treatment.

Self-Check (Board-Style)